20 February 2013
Update on 2004 Background Paper (Written by Saloni Tanna)
Priority Medicines for Europe and the World "A Public Health Approach to Innovation"
Anti-stigma programs have exploded in the United States as well as across
the world in the past decade. Now needed is a more strategic approach to stigma
change, consideration of evaluation strategies that demonstrate its effectiveness.
Q10: For carers of people with dementia, does respite care when compared to care as usual, produce benefits/harm in the specified outcomes?
Q9: For carers of people with dementia, do interventions (psychoeducational, cognitive-behavioural therapy counseling/case management, general support, training of caregivers, multi-component interventions and miscellaneous interventions) when compared to placebo/comparator, produce benefits/harm in... the specified outcomes?
more
Q8: For people with dementia, what is the role of a medical review (including comorbid physical and mental conditions and medication use)?
Q5: For people with dementia, which cognitive/psychosocial interventions (such as cognitive stimulation, cognitive rehabilitation, reality orientation, reminiscence therapy) when compared to placebo/comparator produce benefits/harm in the specified outcomes?
Q3: For behavioural and psychological symptoms in people with dementia, do following drugs, when compared to placebo/comparator, produce benefits/harm in the specified outcomes?
March 28, 2017https://doi.org/10.1371/journal.pmed.1002274
PLoS Med 14(3): e1002274. https://doi.org/10.1371/journal.pmed.1002274
Scoping Question: For adults and children living with HIV, which antiepileptic medications (such as phenobarbital, phenytoin, carbamazepine or valproic acid) produce benefits and/or harms when compared to a placebo or controls?
Q5: What is the added advantage of doing an electroencephalography (EEG) in people with convulsive epilepsy in non- specialist settings in low and middle income countries?
Q8. Should Anti-Epileptic Drug (AED) treatment be started after first unprovoked seizure in non-specialist health settings?
SCOPING QUESTION: For adults and children with medication-resistant convulsive epilepsy, which anti-epileptic medications produce benefits and/or harm in the specified outcomes when compared to a placebo or a comparator?
Q12: Should the treatment be similar in individuals with intellectual disability and epilepsy compared to people with epilepsy only?
This paper focuses on the Sustainable Development Goals related to poverty, economic growth, inequality, health, food production and the environment. It presents concrete examples of the underlying and complex aspects of antibiotic resistance and its impacts across different Sustainable Development ...Goals. The aim of this paper is to inform and stimulate discussions on how to further advance the implementation of 2030 Agenda for Sustainable Development, the Global Action Plan on Antimicrobial Resistance, National Action plans on Antimicrobial Resistance, as well as work within all sectors that affect and are affected by antibiotic resistance
more
This rapid compilation of data analyses provides a ‘stock-take’ of social science and behavioural data related to the on-going outbreak of Ebola in North Kivu, South Kivu and Ituri provinces. Based on data gathered and analysed by organisations working in the Ebola response and in the region mor...e broadly, it explores convergences and divergences between datasets and, when possible, differences by geographic area, demographic group, time period and other relevant variables. Data sources are listed at the end of the document.
more
For the 24th consecutive year, PAHO has published the report Health Situation in the Americas: Core Indicators featuring the latest information on key indicators for the Region of the Americas. This 2018 edition includes data on the 82 core indicators for the countries, territories, and sub regions ...of the Americas, grouped into the following categories: demographic-socioeconomic, health status, risk factors, service coverage, and health systems. Information is also presented on 22 indicators of the Sustainable Development Goals (SDGs).
more
В методических рекомендациях представлены современные подходы к терапии поведенческих и психотических расстройств у пациентов с болезнью Альцгеймера. Ведение т...ких пациентов включает широкий диапазон психофармакотера- певтических средств и психосоциальной помощи больному и его семье. Подчеркивается необходимость проведения полного диагностического обследования, тщательного определения этиологии деменции и исключения других возможных причин поведенческих и психопатологических симптомов. Пособие предназначено для психиатров, неврологов и гериатров.
more
Report for the WHO Meningitis Guideline Revision (May 2014)
Цель: проведение анализа психоэмоциональных расстройств у пациентов с рассеянным склерозом, не по-лучающих никакого лечения по поводу этих нарушений. Материал и м...етоды. Для работы отобрана когорта пациентов с достоверным диагнозом рассеянного склероза, согласно критериям Ч. Позера, в составе 163 че-ловек. Использовался четырехмерный симптоматический опросник для оценки дистресса, депрессии, тревоги и соматизации (4DSq) и самоопросник для оценки симптомов фибромиалгии с оценкой количественных показателей (WPI, SS, FS). Результаты. Показаны различия средних значений уровня дистресса, депрессии, тревоги и соматизации у пациентов с рассеянным склерозом разного пола, возраста, с разным типом течения и длительностью заболевания. Заключение. Нервно-психический статус пациентов зависит от типа течения заболевания, уровень дистресса — от возраста и пола, уровень соматизации — от возраста данной категории больных. В комплексном лечении данной категории больных необходимо использовать помимо патогенетиче-ской терапии симптоматическое лечение, не только оказывающее нейротрофический и вазоактивный эффект, но и влияющее на психоэмоциональный фон пациентов.
http://www.ssmj.ru/system/files/2018_01-1_151-153.pdf
more